Table 3. Association between combined GSTP1 and GSTO1 polymorphisms and the recurrence-free survival of patients treated with epirubicin.

	Epirubicin
	MST*	Log-rank P	Adjusted HR (95% CI)
GSTP1 and GSTO1
AG+GG and AC+AA	31.3		1.00 (reference)
AG+GG and CC	43.3	0.449	0.61 (0.26–1.40)
AA and AC+AA	57.0	0.051	0.30 (0.09–1.08)
AA and CC	83.4	0.001	0.21 (0.08–0.56)

^*Mean survival time was defined as the mean time before recurrence.